Dr. Bradley Rayford Keel, DO

Dr. Keel practices at Georgia Urology PA in Alpharetta, Georgia.

Dr. Keel's NPI, 1003041641, was assigned on May 27, 2009. Dr. Keel holds Tennessee license 2274.

Dr. Keel's primary practice is Georgia Urology PA, at 3400 Old Milton Pkwy, Alpharetta, GA 30005 in Fulton County. The practice phone is (770) 475-7550.

Dr. Keel's primary practice is Georgia Urology PA in Alpharetta, Georgia. Dr. Keel is also affiliated with Erlanger Baroness Hospital. The medical group on file is Southeast Medical Group. Dmand AI also links Dr. Keel to 2 more hospitals, 2 group practices and clinics, 2 home health agencies and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Keel practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Keel's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Keel is board certified in internal medicine by the American Board of Internal Medicine. Dr. Keel is licensed in Tennessee.

CMS data shows 614 Medicare services from Dr. Keel across 10 procedure codes in 2024, for 162 Medicare patients. Medicare paid $33,402 for them. Every service was in an office.

CMS counts 162 Medicare patients who saw Dr. Keel in 2024. The largest group is 65 to 74, with 96 patients. 67% of them have high blood pressure, and 65% have high cholesterol. Their average risk score is 0.96, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Keel's median patient age at 54, with 50% women.

In 2024, Dr. Keel wrote 4,003 Medicare Part D claims for 334 patients. 88% of them were for generic drugs. CMS names the drug for 3,343 of them, across 96 drugs with 11 or more claims each, at $318,309 in total drug cost. In 2023, CMS named 1,355 claims across 57 drugs.

Dr. Keel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Keel as offering telehealth.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Keel. Dr. Keel has published most often in Tenn Med. Dr. Keel's most frequent co-author is Michael Brit.

Dmand AI links Dr. Keel to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Adenocarcinoma of Lung, Biliary Atresia and Low Back Pain.

CMS Open Payments shows 208 general payments to Dr. Keel from 27 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $985.